Gluzamet 80mg/500mg Tablet is a combination oral hypoglycemic agent containing Gliclazide 80mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral insulin sensitivity, contributing to decreased blood glucose levels. The synergistic action of these two agents addresses both insulin deficiency and insulin resistance, making Gluzamet effective in patients inadequately controlled by diet and exercise alone. This combination is particularly beneficial in improving fasting and postprandial blood glucose levels. Gluzamet should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of blood glucose and renal function. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia due to the sulfonylurea component. Dose adjustments and patient education on recognizing hypoglycemia symptoms are essential for safe and effective therapy. Gluzamet 80mg/500mg Tablet offers a convenient and effective option for optimizing glycemic control in type 2 diabetes mellitus.